-+ 0.00%
-+ 0.00%
-+ 0.00%

Roche's CD20/CD3 bispecific antibody Lunsumio successfully reached the primary endpoint in the critical phase III CELESTIMO study for follicular lymphoma.

Zhitongcaijing·09/17/2026 05:09:04
Listen to the news
Roche's CD20/CD3 bispecific antibody Lunsumio successfully reached the primary endpoint in the critical phase III CELESTIMO study for follicular lymphoma.